1. Home
  2. RCMT vs IPHA Comparison

RCMT vs IPHA Comparison

Compare RCMT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RCM Technologies Inc.

RCMT

RCM Technologies Inc.

HOLD

Current Price

$18.85

Market Cap

146.0M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.50

Market Cap

160.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCMT
IPHA
Founded
1971
1999
Country
United States
France
Employees
N/A
174
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.0M
160.7M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
RCMT
IPHA
Price
$18.85
$1.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$30.00
$5.75
AVG Volume (30 Days)
36.6K
12.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.34
N/A
Revenue
$186,737,000.00
N/A
Revenue This Year
$16.29
$28.31
Revenue Next Year
$6.92
N/A
P/E Ratio
$14.58
N/A
Revenue Growth
5.83
N/A
52 Week Low
$14.83
$1.40
52 Week High
$28.19
$2.63

Technical Indicators

Market Signals
Indicator
RCMT
IPHA
Relative Strength Index (RSI) 46.32 31.04
Support Level $19.02 N/A
Resistance Level $21.00 $1.88
Average True Range (ATR) 0.86 0.08
MACD 0.08 -0.02
Stochastic Oscillator 47.87 2.53

Price Performance

Historical Comparison
RCMT
IPHA

About RCMT RCM Technologies Inc.

RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: